Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder

Psychiatry Research

Volumn 189, Issue 3, 2011, Pages 475-477

  Houston, John P ^a,b   Kohler, Jared ^c   Ostbye, Katherine M ^c   Heinloth, Alexandra ^d   Perlis, Roy H ^e  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BioStat Solutions Inc   (United States)

^d SYNEOS HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diplotype; Rs165737; Single nucleotide polymorphisms

Indexed keywords

CATECHOL METHYLTRANSFERASE; DULOXETINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIPLOTYPE; DRUG RESPONSE; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION; GENOTYPE; HAMILTON SCALE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; REMISSION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SEX FACTORS; THIOPHENES;

EID: 80053445478     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.07.002     Document Type: Article

References (9)

1. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
2. Gao X., Starmer J., Martin E.R. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genetic Epidemiology 2008, 32:361-369.
3. Jurinke C., van den Boom D., Cantor C.R., Köster H. Automated genotyping using the DNA MassArray technology. Methods in Molecular Biology 2002, 187:179-192.
4. Nackley A.G., Shabalina S.A., Tchivileva I.E., Satterfield K., Korchynskyi O., Makarov S.S., Maixner W., Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930-1933.
5. Perlis R.H., Fijal B., Adams D.H., Sutton V.K., Trivedi M.H., Houston J.P. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological Psychiatry 2009, 65:785-791.
6. Perlis R.H., Fijal B., Dharia S., Heinloth A.N., Houston J.P. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biological Psychiatry 2010, 67:1110-1113.
7. Tsai S.J., Gau Y.T., Hong C.J., Liou Y.J., Yu Y.W., Chen T.J. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. Journal of Affective Disorders 2009, 113:183-187.
8. Tsao D., Shabalina S.A., Gauthier J., Dokholyan N.V., Diatchenko L. Disruptive mRNA folding increases translational efficiency of catechol-O-methyltransferase variant. Nucleic Acids Research 2011, [Electronic publication ahead of print].
9. Whitmyer V.G., Dunner D.L., Kornstein S.G., Meyers A.L., Mallinckrodt C.H., Wohlreich M.M., Gonzales J.S., Greist J.H. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. The Journal of Clinical Psychiatry 2007, 68:1921-1930.